|
T11284 |
FIDAS-3
|
|
Others
,
Wnt/beta-catenin
,
Methionine Adenosyltransferase (MAT)
|
|
FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for ... |
|
T11285 |
FIDAS-5
|
|
Others
|
|
FIDAS-5, a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM, competitively inhibits S-adenosylmethionine (SAM) binding to MAT2A. It exhibits anticancer activities. |
|
T8445 |
PU02
|
PU-02,6-[(1-Naphthalenylmethyl)thio]-9H-purine |
Apoptosis
,
5-HT Receptor
|
|
PU02 (6-[(1-Naphthalenylmethyl)thio]-9H-purine) is a potent and selective antagonist of 5-HT3 receptor. |
|
T11345L |
Lerociclib dihydrochloride
|
G1T38 dihydrochloride |
CDK
|
|
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively. |
|
T22590 |
AT7519 TFA
|
AT7519 trifluoroacetate |
Others
|
|
AT7519 is a kinase inhibitor (IC50: 0.19, 0.044, 0.51, 0.067, 0.66 and 0.018 μM for CDK1/cyclinB, CDK2/CyclinA, CDK2/Cyclin E, CDk4/CyclinD1, CDK6/Cyclin D3, CDk5/p35). |
|
T11345 |
Lerociclib
|
G1T38 |
CDK
|
|
Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 2nM, 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively. |
|
T15335 |
FN-1501
|
|
FLT
,
CDK
|
|
FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity. |
|
T13202 |
Trilaciclib hydrochloride
|
G1T28 hydrochloride |
CDK
|
|
Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6). |
|
T6924 |
Riviciclib hydrochloride
|
P276-00 |
Apoptosis
,
CDK
|
|
Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3. |
|
T10096L |
Voruciclib
|
|
CDK
|
|
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... |
|
T39957 |
CDK4/6-IN-6
|
|
CDK
|
|
CDK4/6-IN-6 is a potent CDK4/CDK6 inhibitor with Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. |
|
T10898 |
Samuraciclib hydrochloride
|
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis
,
CDK
|
|
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold h... |
|
T6239 |
Palbociclib monohydrochloride
|
PD 0332991 hydrochloride,Palbociclib hydrochloride,Palbociclib (PD-0332991) HCl |
CDK
|
|
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases. |
|
T6312 |
R547
|
Ro 4584820 |
Apoptosis
,
GSK-3
,
PKA
,
CDK
|
|
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1. |
|
T2059 |
Purvalanol A
|
NG-60 |
Apoptosis
,
CDK
,
Autophagy
|
|
Purvalanol A (NG-60) is an effective and cell-permeable CDK inhibitor with IC50 of 70/4/35/850 nM for cdk2-cyclin A/B/E, and cdk4-cyclin D1, respectively. |
|
T6240 |
Palbociclib Isethionate
|
Palbociclib (PD0332991) Isethionate,PD 0332991 isethionate |
CDK
|
|
Palbociclib Isethionate (PD 0332991 isethionate) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases. |
|
T1778 |
AT7519 Hydrochloride
|
AT7519 HCl,AT 7519 hydrochloride salt |
Apoptosis
,
GSK-3
,
CDK
|
|
AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9. |
|
T30600 |
BSJ-03-204
|
BSJ03204 |
|
|
BSJ-03-204 is a selective Cdk4/6 degrader. |
|
T23092 |
NSC 625987
|
|
Others
|
|
Cyclin-dependent kinase (cdk) 4 inhibitor |
|
T12737 |
Riviciclib
|
P276-00 (free base) |
Others
|
|
Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells. |
|
T13309 |
Voruciclib hydrochloride
|
|
CDK
|
|
Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM). |
|
T12355 |
Palbociclib-d8
|
PD 0332991 D8,Palbociclib D8 |
CDK
|
|
Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively). |
|
T72507 |
Palbociclib orotate
|
PD 0332991 orotate |
CDK
|
|
Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively. This compound demonstrates potent anti-proliferative effects and induces cell c... |
|
T11653 |
Indirubin-5-sulfonate
|
|
Others
|
|
Indirubin-5-sulfonate shows inhibitory activity against GSK-3β. Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cycli... |
